

Attorney Docket No.: 6133.214-US

REMARKS:

Applicants respectfully request entry of this amendment as it corrects many typographical errors pointed out by the Examiner in a phone conference on November 22, 2004. Applicants have also amended claim 28 in an effort to correct any problems with that claim that made it objectionable.

The specification has also been amended to correct translation errors.

Applicants are also submitting herewith a terminal disclaimer over the parent patent in this patent family.

Attorney Docket No.: 6133.214-US

CONCLUSION

Applicant's attorney wishes to thank the Examiner for his helpful remarks during their telephone call. Should the Examiner believe that any claims are not in condition for allowance, he should feel free to contact the applicants' attorney.

The commissioner is authorized to charge any payments related to this application, including the fee for the terminal disclaimer, to Novo Nordisk's Deposit Account, No. 14-1447 and to credit any over payments to the same account. Should any petitions for extensions of time be required, applicants respectfully request such petitions and authorize payment of any fees due in connection with them to the above referenced deposit account.

Respectfully submitted,



Date: December 2, 2004

Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE